We are live on ! Find out more
FO

FT Options Portfolio holdings

AUM $66.4M
1-Year Est. Return 18.48%
This Fund
S&P 500
This Quarter Est. Return
-1.61%
1 Year Est. Return
+18.48%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$116M
AUM Growth
+$21M
Cap. Flow
+$284M
Cap. Flow %
244.1%
Top 10 Hldgs %
42.12%
Holding
462
New
171
Increased
79
Reduced
68
Closed
122

Top Buys

Rank Stock Value
1
MDVN
MEDIVATION, INC.
MDVN
+$4.59M
2
BIIB icon
Biogen
BIIB
+$3.56M
3
CALM icon
Cal-Maine
CALM
+$2.79M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.48M
5
AAPL icon
Apple
AAPL
+$2.33M

Sector Composition

Rank Sector Weight
1 Healthcare 41.4%
2 Technology 6.27%
3 Consumer Staples 4.14%
4 Consumer Discretionary 2.26%
5 Materials 1.61%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CHTR icon
251
CALL
Charter Communications
CHTR
$16.2B
$21K 0.02%
+240
New +$51.6K
CI icon
252
PUT
Cigna
CI
$74.5B
$21K 0.02%
600
LRCX icon
253
CALL
Lam Research
LRCX
$392B
$21K 0.02%
+200,000
New +$1.61M
CLVS
254
PUT
DELISTED
Clovis Oncology, Inc.
CLVS
$21K 0.02%
10,000
+5,000
+100% +$73.1K
MNDT
255
DELISTED
Mandiant, Inc. Common Stock
MNDT
$21K 0.02%
+1,293
New +$20.9K
QRVO icon
256
CALL
Qorvo
QRVO
$7.54B
$20K 0.02%
+12,000
New +$600K
AMAT icon
257
PUT
Applied Materials
AMAT
$421B
$19K 0.02%
27,500
+19,400
+240% +$428K
LUMO
258
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$19K 0.02%
8,922
+7,144
+402% +$885K
CXRX
259
CALL
DELISTED
Concordia International Corp. Common Stock
CXRX
$19K 0.02%
+17,400
New +$458K
SAGE
260
PUT
DELISTED
Sage Therapeutics
SAGE
$18K 0.02%
+10,000
New +$333K
RCKT icon
261
CALL
Rocket Pharmaceuticals
RCKT
$376M
$17K 0.01%
42,075
+39,575
+1,583% +$1.39M
TWX
262
CALL
DELISTED
Time Warner Inc
TWX
$17K 0.01%
+40,500
New +$3M
AKBA icon
263
PUT
Akebia Therapeutics
AKBA
$359M
$16K 0.01%
45,000
-156,800
-78% -$1.37M
ARWR icon
264
Arrowhead Research
ARWR
$10.5B
$16K 0.01%
3,039
-76,666
-96% -$437K
FXB icon
265
CALL
Invesco CurrencyShares British Pound Sterling Trust
FXB
$77.6M
$16K 0.01%
+42,700
New +$5.99M
MDLZ icon
266
PUT
Mondelez International
MDLZ
$78.3B
$16K 0.01%
+5,000
New +$218K
MNKD icon
267
PUT
MannKind Corp
MNKD
$1.25B
$16K 0.01%
10,200
-48,980
-83% -$303K
BMRN icon
268
CALL
BioMarin Pharmaceuticals
BMRN
$11.5B
$15K 0.01%
+5,000
New +$425K
DBI icon
269
CALL
Designer Brands
DBI
$290M
$15K 0.01%
+15,000
New +$345K
IBM icon
270
IBM
IBM
$200B
$15K 0.01%
105
-10,368
-99% -$1.48M
LUMN icon
271
PUT
Lumen
LUMN
$6.47B
$15K 0.01%
12,800
-7,200
-36% -$210K
TXN icon
272
PUT
Texas Instruments
TXN
$258B
$15K 0.01%
+7,100
New +$422K
INFY icon
273
PUT
Infosys
INFY
$46.5B
$14K 0.01%
60,000
+42,600
+245% +$399K
RGLS
274
DELISTED
Regulus Therapeutics
RGLS
$14K 0.01%
+42
New +$30.1K
TAP icon
275
PUT
Molson Coors Class B
TAP
$7.68B
$14K 0.01%
6,600
+4,100
+164% +$403K

Similar funds

FT Options's Q2 2016 Portfolio in Review

As of Q2 2016, FT Options held 462 positions worth $116M, up 22% from $95.5M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

FT Options deployed $284M of net new capital in Q2 2016, opening 171 new positions and adding to 79 existing holdings. Its largest new stake was Bristol-Myers Squibb: 35,075 shares worth $2.58M.

By sector, the portfolio is most concentrated in Healthcare at 41% of assets, down from 48% a quarter earlier, followed by Technology and Consumer Staples.

On the sell side, the largest reduction was Gilead Sciences, an estimated $2M trimmed.

  • FT Options's largest Q2 2016 buy was Bristol-Myers Squibb: 35,075 shares worth $2.58M.
  • FT Options added most to MEDIVATION, INC. in Q2 2016, an estimated $4.59M increase.
  • FT Options's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $2M.
  • FT Options fully exited Baxter International in Q2 2016, selling an estimated $4.11M.
  • FT Options's ten largest holdings make up 42% of its $116M portfolio in Q2 2016.
  • FT Options opened 171 new positions and closed 122 in Q2 2016.
  • FT Options's portfolio value rose 22% quarter-over-quarter to $116M.

Based on FT Options's 13F filing for Q2 2016, filed 12 Aug 2016.